Krystal Biotech Inc. (KRYS)
155.66
2.42 (1.58%)
At close: Feb 18, 2025, 3:59 PM
163.19
4.84%
After-hours: Feb 18, 2025, 06:21 PM EST
undefined% (undefined)
| Bid | 157.2 |
| Market Cap | 4.48B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.78 |
| PE Ratio (ttm) | 87.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 180.53 |
| Volume | 309,065 |
| Avg. Volume (20D) | 251,094 |
| Open | 152.62 |
| Previous Close | 153.24 |
| Day's Range | 152.62 - 157.39 |
| 52-Week Range | 107.50 - 219.34 |
| Beta | undefined |
About KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive con...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 229
Stock Exchange NASDAQ
Ticker Symbol KRYS
Website https://www.krystalbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for KRYS stock is "Buy." The 12-month stock price forecast is $212, which is an increase of 36.19% from the latest price.
Buy 85.71%
Hold 14.29%
Sell 0.00%
Next Earnings Release
Krystal Biotech Inc. is scheduled to release its earnings on Feb 19, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+7.45%
Krystal Biotech shares are trading higher after St...
Unlock content with
Pro Subscription
9 months ago
-2.58%
Krystal Biotech shares are trading lower after the company reported Q1 financial results.
